Braveheart Bio Launches with $185M Series A Aiming to Transform Care of Hypertrophic Cardiomyopathy
PR Newswire —
Leadership brings experience in company building, advancing late-stage clinical programs, and deep understanding of cardiovascular drug development Company intends to rapidly advance BHB-1893 into late-stage clinical development Board to include Chris Viehbacher as Chair, with investor...